

Evaluation P24011
9/5/24 (Live)
9/25/24-9/24/25

- 1) First Name* (*All with * may be collected otherwise – ensure that we collect either automatically or with question)**
- 2) Last Name***
- 3) Email Address***
- 4) Organization/Affiliation***
- 5) City***
- 6) State***
- 7) Zip Code***
- 8) Country***

Please provide your unique provider identifier (ex. NPI in US, BIG in Netherlands, etc).
Please provide your License number and State (if applicable)

Which of the following best represents your profession?

- a. Physician
- b. NP
- c. PA
- d. Pharmacist
- e. Other

What is your primary specialty?

- a. Hematology/Oncology – cellular therapists
- b. Hematology/Oncology – general
- c. Hematology/Oncology – pediatric
- d. Pathology
- e. Other

How long have you been in practice?

- a. <1 year
- b. 1-5 years
- c. 6-10 years
- d. 11-15 years
- e. >15 years

What is your primary work setting?

- a. Community hospital/clinic
- b. Academic medical center/teaching hospital
- c. Private practice
- d. Government/VA facility
- e. Other

On average, how many individuals with EBV+ PTLD do you see per month?

- a. ≤5
- b. 6-10
- c. 11-15
- d. >15
- e. N/A

After participating in this continuing education activity, how confident are you in your ability to treat and manage patients with EBV+ PTLD?

- A. Not at all confident
- B. Somewhat confident
- C. Confident
- D. Highly confident

Rate your agreement with the following statements (1=strongly disagree, 2=disagree, 3=agree, 4=strongly agree)

- a. This activity supported the achievement of the learning objective(s)
- b. The faculty displayed expertise in the subject matter
- c. The format, teaching, and learning methods were appropriate
- d. The content was evidenced based

Was this activity fair, balanced, and free of bias for or against any product?

- a. Yes
- b. No (If you answered "No," please describe the particular content within the activity that exhibited bias.)

Based upon your participation in this activity, do you intend to change your practice behavior?

- 1. Assess the impact and prevalence of EBV+ PTLD within my clinical practice**
 - a. I do plan to implement changes in my practice based on the information presented
 - b. My current practice has been reinforced by the information presented
 - c. I need more information before I will change my practice
- 2. Differentiate among current and emerging prognostic scoring systems for EBV+ PTLD in order to inform treatment decisions**
 - a. I do plan to implement changes in my practice based on the information presented
 - b. My current practice has been reinforced by the information presented
 - c. I need more information before I will change my practice
- 3. Evaluate the latest clinical evidence of emerging treatment options for EBV+ PTLD, based on safety, efficacy, mechanism of action, treatment-**

and disease-specific factors to determine optimal treatment strategies for patients with EBV+ PTLD

- a. I do plan to implement changes in my practice based on the information presented
- b. My current practice has been reinforced by the information presented
- c. I need more information before I will change my practice

As a member of the healthcare team, I plan to implement the following practices after participating in this educational activity (check all that apply):

- a. Seek input from the team to better understand how my role and responsibilities will improve patient outcomes
- b. Apply tools and techniques for better communication with patients and caregivers
- c. Work with my team to improve patient care and safety
- d. Utilize appropriate specialists and clinical resources to improve health outcomes
- e. Other (please specify)

Indicate the barriers that might prevent you from applying the knowledge and/or skills gained from the activity to your practice or organization (check all that apply):

- a. Lack of knowledge regarding how treatment aligns with prognostic factors
- b. Lack of knowledge regarding how treatment aligns with clinical guidelines
- c. Lack of time/resources to consider change
- d. Lack of patient population with EBV+ PTLD
- e. Lack of convincing evidence to warrant change
- f. Lack of access to treatment options/clinical trials
- g. Other (please specify)

Did the activity provide strategies to overcome the following barriers? (check all that apply):

- a. Lack of knowledge regarding how treatment aligns with prognostic factors
- b. Lack of knowledge regarding how treatment aligns with clinical guidelines
- c. Lack of time/resources to consider change
- d. Lack of patient population with EBV+ PTLD
- e. Lack of convincing evidence to warrant change
- f. Lack of access to treatment options/clinical trials
- g. Other (please specify)